13 results about "LIN28" patented technology

A simpler and more efficient method for reprogramming human somatic cells into induced pluripotent stem cells. According to the method, three transcription factors of OCT4, SOX2, and LIN28 are simultaneously transferred into somatic cells, and then reprogramming is performed under the co-induction of four small molecules of Peficitinib, VTP50469, SB203580, and FPFT-2216, wherein the peripheral blood reprogramming efficiency thereof can reach 0.02%, the induction period is only 14-16 days, and the system is stable.

Provided herein are perfusion systems (e.g., a perfusion system with an acoustic volume sensor) that deliver a composition comprising at least one agent that induces expression of OCT3 / 4, SOX2, c-MYC, KLF4, N.ANOG, and / or LIN28 in the kidney. Also provided herein are methods and compositions suitable for use with the perfusion systems.

Provided herein are perfusion systems (e.g., a perfusion system with a an acoustic volume sensor) that deliver a composition comprising at least one agent that induces expression of OCT3 / 4, SOX2, c-MYC, KLF4, NANOG, and / or LIN28 in an organ (e.g., a kidney, a liver, a. heart, a lung, a pancreas). Also provided herein are methods and compositions suitable for use with the perfusion systems.

Improved compositions and methods for producing iPSCs are needed. [Solution] This specification provides a recombinant circular RNA comprising at least one protein-coding nucleic acid sequence, wherein the protein-coding nucleic acid sequence encodes a reprogramming factor (e.g., a transcription factor), and the reprogramming factor is Oct3 / 4, Klf4, Sox2, Nanog, Lin28, c-Myc, or L-Myc, or a fragment or variant thereof. This specification also provides a method for producing induced pluripotent stem cells (iPSCs), comprising contacting somatic cells with at least one of the recombinant circular RNAs described herein and maintaining the cells under conditions that will result in reprogrammed iPSCs.

A simpler and more efficient method for reprogramming human somatic cells into induced pluripotent stem cells. According to the method, three transcription factors of OCT4, SOX2, and LIN28 are simultaneously transferred into somatic cells, and then reprogramming is performed under the co-induction of four small molecules of Peficitinib, VTP50469, SB203580, and FPFT-2216, wherein the peripheral blood reprogramming efficiency thereof can reach 0.02%, the induction period is only 14-16 days, and the system is stable.

The present disclosure relates to compounds of formula (I) and compositions comprising the compounds. The present disclosure also relates to methods of treating cancer.

The application discloses a preparation method of cat induced pluripotent stem cells, which comprises the following steps: constructing piggyBac transposon plasmids carrying cat source OCT4, SOX2, KLF4 and c-MYC four factors in series, piggyBac transposon plasmids carrying cat source or pig source NANOG and LIN28 two factors in series and piggyBac transposon plasmids carrying monkey kidney virus SV40LT plasmids, and transfecting the plasmids into cat fetal fibroblasts; picking up cloned cells with embryonic stem cell morphologies, and carrying out subculture of cell clones meeting the characteristics of embryonic stem cells through identification and screening, so that the cat induced pluripotent stem cells are obtained. The preparation method of the cat induced pluripotent stem cells is safe, efficient and has good differentiation potential, lays a scientific foundation for researching in-vitro culture conditions of feline ESCs and establishment of feline iPSCs, and lays a scientific foundation for further cultivating cloned cats and gene modified cats and researching in related disease mechanisms, screening drugs and regeneration and repair.

This invention provides a method for producing induced pluripotent stem cells. [Solution] The present disclosure includes the step of producing induced pluripotent stem cells by expressing exogenous nucleic acids encoding proteins OCT3 / 4, SOX2, KLF4, LIN28, and L-MYC, as well as p53-shRNA, in umbilical cord amniotic stem cells under conditions suitable for reprogramming stem cells. The present disclosure also includes the induced pluripotent stem cell population obtainable by this method, the induced pluripotent stem cell population obtained by this method, a pharmaceutical composition containing the induced pluripotent stem cells of the present invention, a method for differentiating the induced pluripotent stem cells of the present invention, a pharmaceutical composition containing the differentiated induced pluripotent stem cells obtained by this method, and a method for treating congenital or acquired degenerative disorders in a subject, comprising the step of administering target cells differentiated from pluripotent stem cells to the subject.

Provided is a use of a skin reprogramming factor formulation in the preparation of a drug for promoting skin wound healing. The skin reprogramming factor formulation comprises 2-4 mole parts of an mRNA nucleic acid molecule encoding an Oct4 transcription factor, 1 mole part of an mRNA nucleic acid molecule encoding a Sox2 transcription factor, 1 mole part of an mRNA nucleic acid molecule encoding a Klf4 transcription factor, 1 mole part of an mRNA nucleic acid molecule encoding a Glis1 transcription factor, and 1 mole part of an mRNA nucleic acid molecule encoding a Lin28 transcription factor. After the skin reprogramming factor formulation is introduced into a skin wound, various reprogramming factors are generated by means of skin cells on the wound, the reprogramming factors can be expressed at full-thickness skin to efficiently repair damaged tissue, and the reprogramming factors can quickly repair the skin wound and reduce scars.

Provided are a skin reprogramming factor formulation, a biological material, and uses. The skin reprogramming factor formulation comprises 2-4 mole parts of an mRNA nucleic acid molecule encoding an Oct4 transcription factor, 1 mole part of an mRNA nucleic acid molecule encoding an Sox2 transcription factor, 1 mole part of an mRNA nucleic acid molecule encoding a Klf4 transcription factor, 1 mole part of an mRNA nucleic acid molecule encoding a Glis1 transcription factor, and 1 mole part of an mRNA nucleic acid molecule encoding an Lin28 transcription factor. When the skin reprogramming factor formulation is introduced into the skin, in situ reversal of skin aging is achieved, the expression of skin aging related genes is down-regulated, and a good skin wrinkle eliminating effect is achieved; in addition, hair follicle related genes are up-regulated, so that hair follicle proliferation can be promoted, and hair growth can be promoted.

The invention relates to the technical field of biological materials, in particular to a method for reversing ips cells through peripheral blood mononuclear cells and application, and the method comprises the following steps: separating the peripheral blood mononuclear cells through a density gradient centrifugation method, and pretreating the peripheral blood mononuclear cells; meanwhile, a reprogramming factor mRNA is encapsulated in an LNP carrier, and the reprogramming factor comprises Oct4, Sox2, Klf4, Glis1, Nanog and Lin28, so that an LNP-reprogramming factor compound is obtained; and introducing the LNP-reprogramming factor compound into the pretreated mononuclear cells through an electroporation method, and carrying out induced culture on the mononuclear cells until the IPS cells are obtained. The method provides a reliable technical scheme for efficient and high-quality preparation of the peripheral blood-derived iPS cells.

A reprogramming factor preparation for promoting tissue cell proliferation and a use. The preparation comprises an mRNA encoding an alphavirus mutant replicase, an mRNA encoding an Oct4 transcription factor, an mRNA encoding a Sox2 transcription factor, an mRNA encoding a Klf4 transcription factor, an mRNA encoding a Glis1 transcription factor, and an mRNA encoding a Lin28 transcription factor. After the molar proportions of the mRNA expressing a replicase and the mRNAs expressing different transcription factors are adjusted and the above reprogramming factor preparation is introduced into the myocardium, synthesis of the transcription factors are achieved by means of the alphavirus mutant replicase, promoting cell division of cardiomyocytes and increase the number of cardiomyocytes, improving the cardiac function of an injured heart, especially improving the cardiac function after acute heart injuries; additionally, uncontrolled growth of cardiomyocytes is avoided, and hypertrophic cardiomyopathy and heart failure are avoided.

Provided are an adoptive immune cell, and a preparation method therefor and the use thereof. The adoptive immune cell have a reprogramming factor expression system introduced therein, and can express one or more of an Oct4 transcription factor, a Sox2 transcription factor, a Klf4 transcription factor, a cMyc transcription factor, a Glis1 transcription factor and a Lin28 transcription factor. By means of reversing aging, the adoptive immune cell has an improved quantity and quality when cultured in vitro and has a prolonged survival time in vivo, and thus the effect of adoptive cell therapy is improved.